'Institute' Swedish News Blog posts

SEATTLE, Jan. 31, 2013 – Swedish Cancer Institute (SCI) recently announced the appointment of Thomas D. Brown, M.D., MBA, as its new executive director. Dr. Brown will join SCI March 16.

SEATTLE, Oct. 26, 2012 – Swedish Medical Center's seven-year fund-raising initiative, called The Campaign for Swedish, has raised $103 million, exceeding its initial $100 million fund-raising goal in approximately five-and-a-half years. The Campaign, launched to help improve patient care and treatment options throughout the Swedish system, is the largest fund-raising effort undertaken by the private, non-profit health system to date.

SEATTLE, Aug. 27, 2012 – Since its opening in 2008, the Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment (the Ivy Center) at Swedish Medical Center's Neuroscience Institute has led the expansion drive of major research projects and expanded treatment options for patients living with brain cancer in the Pacific Northwest and throughout the world. The Ivy Center was founded in 2008 to create a world-class treatment and research facility focused on delivering excellent patient care and advancing progress toward more effective treatments for brain cancer.

SEATTLE, March 30, 2012 - Seattle NBC affiliate KING Television (Channel 5) aired a story during their 5 p.m. PT newscast tonight about a relatively new, FDA-approved medical device called LifeVest ®. The wearable defibrillator is a treatment option for sudden cardiac arrest that offers patients advanced protection and monitoring as well as improved quality of life.

LifeVest is the first wearable defibrillator. Unlike an implantable cardioverter defibrillator (ICD), the LifeVest is worn outside the body rather than implanted in the chest. This device continuously monitors the patient's heart with dry, non-adhesive sensing electrodes to detect life-threatening abnormal heart rhythms. If a life-threatening rhythm is detected, the device alerts the patient prior to delivering a treatment shock, and thus allows a conscious patient to delay the treatment shock. If the patient becomes unconscious, the device releases a Blue™ gel over the therapy electrodes and delivers an electrical shock to restore normal rhythm.